Travere Therapeutics, Inc. TVTX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s business segments — net loss?
- Travere Therapeutics, Inc. (TVTX) reported business segments — net loss of -$37.1M in Q1 2026.
- How has Travere Therapeutics, Inc.'s business segments — net loss changed year-over-year?
- Travere Therapeutics, Inc.'s business segments — net loss increased by 10.0% year-over-year, from -$41.23M to -$37.1M.
- What is the long-term trend for Travere Therapeutics, Inc.'s business segments — net loss?
- Over 2 years (2022 to 2024), Travere Therapeutics, Inc.'s business segments — net loss has grown at a 7.5% compound annual growth rate (CAGR), from -$278.48M to -$321.55M.
- What does business segments — net loss mean?
- This represents the bottom-line financial result for a specific business segment after accounting for all associated revenues, operating expenses, and tax obligations. A net loss indicates that the costs of operating the segment, including research and development and administrative overhead, exceed the revenue generated during the period. It serves as a primary indicator of the segment's current profitability and its contribution to the overall corporate financial position.